US Expansion Readiness Saluda has launched EVA sensing technology in the United States and is rolling out the Evoke SmartLoop system, supported by leadership changes and recent public financing. This signals strong capacity to scale sales teams, clinician education, and reimbursement initiatives in US pain management and neuromodulation markets.

Data Driven Edge The Evoke System leverages ECAP-controlled, closed-loop therapy with real-time neural feedback updated millions of times per day, providing a clear differentiator for hospitals and clinics seeking consistent outcomes and payer value. This creates upsell opportunities to programs prioritizing precision dosing and data-driven results.

Growth Capital Recent public listing and funding provide capital to expand geographic reach, generate additional clinical evidence, and broaden adoption of EVA sensing technology, enabling strategic conversations with large hospital networks and distributors.

Ecosystem Partnerships EVA integration within the Evoke SmartLoop platform invites partnerships with EMR/EHR vendors, health systems, and neuromodulation distributors to streamline adoption, data capture, and outcomes-based reimbursement strategies.

Strategic Customers Target high-potential segments such as pain management centers, spine and neuromodulation specialists, and academic medical centers investing in advanced neuromodulation solutions, presenting clear upsell opportunities for EVA-enabled closed-loop SCS adoption.